Form 10-K Arcus Biosciences, Inc. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
H.C. Wainwright Upgrades Arcus Biosciences (RCUS) to Buy
February 26, 2025 6:06 AM ESTH.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (NYSE: RCUS) from Neutral to Buy with a price target of $24.00.
The analyst comments "Initial cas + cabo data expected in mid-2025; we are increasingly positive on opportunity given cas efficacy vs belzutifan. The ARC-20 study evaluating casdatifan (cas) monotherapy and in combo with other agents in clear cell renal cell carcinoma (ccRCC) has enrolled ~40 patients in the cas + cabozantinib (cabo) cohort, which is meant to evaluate the same combo and patient population as the Phase 3 PEAK-1 study expected to initiate in 2Q25... More
